Loading...
Loading...
- NRx Pharmaceuticals Inc NRXP shares are down Friday as it evaluated whether there are any conditions or events that could raise substantial doubt about its ability to continue as a going concern within one year beyond the date of filing its annual report.
- The company has generated no revenues, has incurred operating losses since inception, and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable.
- Related: Monitoring Board Recommends NRx Pharma's Suicidal Bipolar Depression Study To Continue Enrollment.
- The company depends on obtaining the necessary equity and/or debt financing to continue operations and cannot make any assurances that sales of its lead product, NRX-101, will commence in the near term, or that additional financing will be available to it.
- This could negatively impact the company's business and operations and could also reduce the company's operations.
- As of December 31, 2022, the cash balance was $20.1 million.
- Price Action: NRXP shares are down 10.58% at $0.6691 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in